NanoBioMagnetics (NBMI) is a nanobiomaterials company pioneering an emerging area of nanomedicine referred to as organ-assisting-device (OAD) technologies, in which magnetically responsive nanoparticles (MNP), under the influence of external shaped magnetic fields, are magnetically vectored to cause or drive a desired physiological event. OAD healthcare applications are being developed under two proprietary platforms:
Site-Specific Drug Delivery: MNP-therapeutic constructs, under the influence of external shaped magnetic fields, are vectored to a target site, followed by cell uptake and subsequent release of the bioactive component.
Biostable Implants: MNP constructs, implanted in tissue, nanomechanically drive tissue movement or vibration under the influence of an external oscillating magnetic field.
As a nanobiomaterials company, NBMI has established collaborations with major research institutions for the validation of its OAD healthcare technologies. When successfully transferred to the clinical sector, OAD technologies will provide the physician and patient with new more effective therapeutic options for addressing the medical requirements of disease management.
The company's business model calls for the development and validation of OAD healthcare applications through collaborations with academic and pharma organizations, followed by a spin-off of a business venture in conjunction with pharma partnerships. Once established, pharma partners will move the respective OAD technologies forward through clinical evaluations and FDA clearances.
NBMI's proprietary magnetic vectoring technology also creates a pipeline of OAD technology applications, also under some stage of collaborative development, that include:
Early stage cancer diagnostics
Placement and positioning of stem cells
Magnetic based biosensors
Vectoring of down-regulating genes
US Patents have been awarded for hearing amplification, and the targeted delivery of bioactive compounds. The company currently has 8 patents applications under review.
...............................
The Team.........
Charles Seeney, M.S. Polymer Science, is Founder and President of NanoBioMagnetics (NBMI), which is the fourth technology venture startup under his direction and leadership. He previously was Founder and President of NanoSource Technologies, Inc. (NSTI), whose IP was acquired by the DuPont Corp (2002). He holds a B.S. in chemistry from Lincoln University of Missouri, and his industrial career spans 25+ years since receiving an M.S. in Polymer Chemistry from the University of Akron, OH. He began his career as a Research Scientist with Fortune 200 Companies, eventually becoming a Director of R&D. In the mid-80’s, his career interests turned to Technology Deployment when he started an internal venture, IMCERA Bioproducts, for a Fortune 200 Company which was eventually acquired by the Mallinckrodt Chemical SBU. Over his career, Seeney has been awarded 18 US Patents, with ten applications currently pending, and has also been published in peer reviewed journals.
Dr. Jim Klostergaard, Professor of Molecular and Cellular Oncology at the University of Texas M. D. Anderson Cancer Center, Houston, TX. He also serves as NBMI's Scientific Advisor while leading the collaboration at M. D. Anderson developing the concept of tumor-specific magnetical vectoring of chemotherapeutics using magnetically responsive nanoparticles as carriers. Dr. Klostergaard's research interests and activites include tumor necrosis factor, drug carriers, sphingolipids, and drug copolymers. His work also on paclitaxel pro-drug formulations in taxol-resistant human ovarian carcinoma nude mouse xenograft models that show improved survival and even achieved some cures in small animal models. His collaborative work with NBMI has focused on the magnetic vectoring of paclitaxel constructs in small animal breast and ovarian xenograft tumor models.
William Yuill, Ph.D., Physical Chemistry, is NBMI's PI in the areas of nanomaterial physics and magnetics. Prior to his retirement in 2002, he served as Program Manager for Kerr-McGee Corporation, where one of his efforts was devoted to nanoscale processes for the reduction of titanium dioxide. He has significant industrial experience in heat transfer, fluid flow, process modeling and reactor design as well as expertise in aerosol processes. Dr. Yuill is listed as co-inventor or sole inventor on 12 US Patents. Dr. Yuill provides the team with expertise in nanoparticle physics and nanofabrication methods based on aerosol processes.
Donald Gibson, M.S., Biochemistry, brings twenty plus years of academic and industrial research experience to NBMI. As Associate Director of Operations for a medical diagnostic venture, he was responsible for maintaining GMP protocols in the production of key materials for the diagnostic device. As Senior Scientist, Mr. Gibson will provide process development expertise in the design of specific nanoparticle configurations for the client. Mr. Gibson is published in several peer-reviewed journals and is an Adjunct Professor of Chemistry at the University of Central Oklahoma.
NanoBioMagnetics, Inc 124 N Bryant Ave, Ste C3 Edmond, OK 73034 Ph: 405.216.3366 <> TF: 855.842.6771 www.nanobmi.com www.vicorptech.com
